| Literature DB >> 27882141 |
Ming Zeng1, Yan Zhi1, Wenjun Liu1, Wei Zhang1, Jinxiong Xu1.
Abstract
Transplanted free skin flaps are often needed to treat deep burns; their survival, however, is less than optimal. This study examined whether local low-dose insulin injections can promote flap survival and wound healing after surgery. A total of 165 patients who underwent free skin flap transplantation for simple deep burns were enrolled in the study and divided into 5 groups of 33 patients each: Blank control group (no local subcutaneous drug injections), saline control group (saline injections), low-dose insulin group (0.5 units regular insulin injections), medium-dose group (1.0 units regular insulin injections) and high-dose group (2.0 units regular insulin injections). Wound healing and flap survival conditions were assessed and compared among groups. The best wound healing rate found was that of the low-dose insulin injection group where all the parameters measured improved significantly: The healing time was shorter; the blood flow volume, the flap survival, the number of fibroblasts and new vessels increased; the re-epithelialization occurred faster; the infiltration of inflammatory cells was reduced; the expression levels of heat shock protein-90, vascular endothelial growth factor, transforming growth factor-β and interleukin-1 were higher; and the plasma glucose levels only fluctuated slightly. The results clearly demonstrate that a local low-dose insulin regime after flap transplantation can accelerate the healing time and improve the surgical outcome without exerting detrimental secondary effects on the glucose plasma level of deep burn patients.Entities:
Keywords: deep burn; heat shock protein-90; interleukin-1 CD31 immunohistochemistry; low-dose insulin; transforming growth factor-β; transplanted flap; vascular endothelial growth factor; wound healing
Year: 2016 PMID: 27882141 PMCID: PMC5103771 DOI: 10.3892/etm.2016.3749
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of inter-group baseline data.
| Group | Case | Male/female | Age | Course of disease, h | Deep II° | III° | Extent of burn (% TBSA) | Limbs | Chest | Abdomen | Back |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blank control | 33 | 19/14 | 52.4±10.3 | 1.2±0.4 | 17 | 16 | 35.6±7.8 | 16 | 3 | 4 | 10 |
| Saline control | 33 | 20/13 | 51.3±11.4 | 1.3±0.5 | 18 | 15 | 36.4±7.2 | 18 | 2 | 2 | 11 |
| Low dose | 33 | 21/12 | 53.2±12.2 | 1.4±0.7 | 19 | 14 | 35.8±7.5 | 17 | 3 | 3 | 10 |
| Median dose | 33 | 20/13 | 54.5±13.5 | 1.1±0.6 | 16 | 17 | 36.3±7.6 | 15 | 4 | 2 | 12 |
| High dose | 33 | 21/12 | 52.7±12.6 | 1.3±0.5 | 18 | 15 | 35.9±7.7 | 16 | 5 | 3 | 9 |
| F (χ2) | 0.357 | 0.625 | 0.514 | 0.633 | 0.249 | 3.335 | |||||
| P-value | 0.986 | 0.349 | 0.636 | 0.959 | 0.302 | 0.993 |
Comparison between wound healing and flap survival conditions.
| Group | Wound healing time, days | 7 days healing rate, % | 14 days healing rate, % | Total flap survival rate, % | 7 days survival rate, % | 14 days survival rate, % |
|---|---|---|---|---|---|---|
| Blank control | 27.5±4.2 | 47.2±10.3 | 53.9±11.2 | 70.5±6.9 | 61.5±7.2 | 68.5±7.4 |
| Saline control | 26.6±4.5 | 48.8±11.2 | 55.7±11.6 | 72.3±6.8 | 63.2±7.3 | 69.7±7.5 |
| Low dose | 18.2±3.3 | 72.8±8.6 | 86.5±10.4 | 92.5±5.4 | 83.4±6.3 | 90.6±6.6 |
| Medium dose | 22.4±5.2 | 56.9±12.3 | 70.3±12.6 | 78.8±6.6 | 72.1±7.8 | 76.5±7.3 |
| High dose | 31.3±5.6 | 33.4±14.2 | 48.4±15.5 | 67.9±6.3 | 64.4±7.1 | 65.3±7.2 |
| F | 8.245 | 9.654 | 10.772 | 7.648 | 8.524 | 8.639 |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Figure 1.Flowmetry of representative biopsy tissues from different groups at 7 and 14 days.
Figure 2.Microscopic (magnification, ×100) images of representative biopsy tissues from each group at 7 and 14 days.
Expression levels of HSP-90, VEGF, TGF-β and IL-1.
| HSP-90, ng/ml | VEGF, µg/ml | TGF-β, pg/ml | IL-1, pg/ml | |||||
|---|---|---|---|---|---|---|---|---|
| Group | 7 days | 14 days | 7 days | 14 days | 7 days | 14 days | 7 days | 14 days |
| Blank control | 25.2±6.4 | 16.8±6.5 | 14.3±8.2 | 12.9±8.4 | 45.9±15.2 | 24.8±11.2 | 73.2±32.6 | 39.7±14.2 |
| Saline control | 26.3±6.9 | 17.2±6.8 | 15.2±7.6 | 13.5±7.8 | 44.8±14.7 | 26.5±11.4 | 75.7±36.7 | 36.5±13.9 |
| Low dose | 63.4±12.3 | 42.5±12.6 | 44.8±10.3 | 36.5±10.5 | 156.3±43.2 | 85.7±36.5 | 247.3±62.4 | 112.3±48.5 |
| Medium dose | 52.6±13.7 | 33.7±13.9 | 32.8±11.2 | 27.6±11.3 | 120.5±45.7 | 64.5±32.4 | 215.8±70.2 | 86.4±36.5 |
| High dose | 24.8±6.6 | 15.5±6.3 | 14.4±7.2 | 12.7±7.3 | 43.2±15.8 | 23.9±10.3 | 69.8±35.5 | 37.2±12.5 |
| F | 10.523 | 8.659 | 8.645 | 9.203 | 15.426 | 13.258 | 14.527 | 13.625 |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
HSP-90, heat shock protein-90; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor-β; IL-1, interleukin-1.
Figure 3.Microvessel quantity by immunohistochemistry using CD31 antibodies. Microscopic (magnification, ×40) view of representative biopsy tissues from each group at 7 and 14 days.
Comparison of blood sugar level (mmol/l).
| Group | Before treatment | 7 days | 14 days |
|---|---|---|---|
| Blank control | 7.6±1.5 | 7.1±1.3 | 6.3±1.1 |
| Saline control | 7.7±1.4 | 6.9±1.6 | 6.4±1.3 |
| Low dose | 7.5±1.5 | 7.0±1.4 | 6.5±1.2 |
| Medium dose | 7.5±1.3 | 6.8±1.2 | 6.3±0.9 |
| High dose | 7.6±1.4 | 6.5±1.1 | 6.1±1.6 |
| F | 0.625 | 4.625 | 4.967 |
| P-value | 0.754 | 0.063 | 0.052 |